NCT00743431View on ClinicalTrials.gov

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

224

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Ovarian Neoplasms
Interventions
DRUG

Caelyx (Pegylated Lyposomal Doxorubicin)

Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00743431 - Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) | Biotech Hunter | Biotech Hunter